top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
iScreen Shoter - 20261028172009135.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
Frame 1000008569.png
Frame 1000008568.png
4acc1a9d-ced8-4f58-a79e-cd2ac6fe752e.png
Frame 1410148109.png
Frame 100000825.png
Frame i1000008267.png
Frame 1410148108.png
Frame 10000082699.png
Fra 1000008266.png
Frame 1000i008268.png
Frame 1410148110.png
Frame 100070.png
Frame 1410148111.png
valve.png

​About

About

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Background: A coronary artery calcium (CAC) score of zero using the conventional Agatston scoring method (Agatston-1.0) is associated with a very low risk of cardiovascular events, a concept commonly referred to as the "Power of Zero." However, a small proportion of individuals with CAC=0 still develop coronary heart disease (CHD). Agatston-1.0 relies on thick CT slices (2.5–3.0 mm) and a fixed attenuation threshold (≥130 Hounsfield Units), which may fail to detect early, small, low-density, or partially calcified coronary plaques. Agatston-2.0 is a novel artificial intelligence (AI) framework that performs automated coronary artery segmentation and continuous voxel-wise calcium quantification without using fixed density thresholds. The framework is compatible with CT scans acquired with slice thicknesses of ≥0.2 mm and generates an AI-derived coronary artery calcium score (AI-CAC).


Objectives: To evaluate the prognostic value of Agatston-2.0 for cardiovascular risk stratification among individuals with a baseline conventional CAC score of zero.


Methods: A total of 3,965 participants with baseline CAC=0 were pooled from the Multi-Ethnic Study of Atherosclerosis (MESA; n=2,816) and the Framingham Heart Study (FHS; n=1,149). Associations between AI-CAC findings and incident coronary heart disease were assessed using Cox proportional hazards models with up to 20 years of follow-up.


Results: Agatston-2.0 detected an AI-CAC score greater than zero in 862 participants (21.7%) who had been classified as CAC=0 by the conventional Agatston method. Participants with AI-CAC>0 experienced a significantly higher 20-year incidence of coronary heart disease compared with those with AI-CAC=0 (7.7% vs. 3.8%, p<0.0001). After adjustment for traditional cardiovascular risk factors, AI-CAC>0 remained independently associated with incident CHD (hazard ratio [HR] 1.71; 95% confidence interval [CI], 1.18–2.47). In addition, AI-CAC>0 was a strong predictor of progression to a positive conventional CAC score during follow-up (adjusted HR 1.95; 95% CI, 1.70–2.24).


Conclusions: The Agatston-2.0 AI framework identifies clinically meaningful coronary calcification in individuals who are classified as CAC=0 using the conventional Agatston scoring method. If these findings are validated in additional prospective cohorts, Agatston-2.0 has the potential to redefine coronary calcium scoring and become the new clinical standard for cardiovascular risk assessment.

Latest Publications

Collabrators

Ali Hashemi

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Anthony Reeves PhD.

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Amir Azimi MD.

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Kyle Atlas

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Jakob Wasserthal

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Seyed Reza Mirjalili MD.

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Chenyu Zhang

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Conference Presentations

Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png
iScreen Shoter - 20261104171348520.jpg

©2026 HeartLung Corporation. All Rights Reserved. U.S. Patent Nos. 12,620,494; 12,599,350; 11,610,686. Licensed U.S. Patent Nos. 9,119,590 and 10,695,022. U.S. Patent Applications Pending: 19/390,544; 19/403,750; 19/643,672; 19/728,738; 19/741,766; 18/652,123; 18/771,542; 19/390,629; 19/417,345; 19/467,802; 19/565,385; 19/682,416; 19/690,066. International PCT Applications: PCT/US2025/058510; PCT/US2025/061047; PCT/US2025/058505; PCT/US2026/013566; PCT/US2026/024304. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoLiver, AutoChamber, AutoLung and other product names and trademarks displayed on this website are protected by applicable intellectual property laws. All rights reserved.

bottom of page